Sunday, February 22, 2026
ISSN 2765-8767
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us

A conversation with Miss Sandra Lamb, an award winning journalist and author

We discuss Miss Lamb’s experiences during the pandemic and glean her thoughts on how it affected the quality of writing among journalists. She explains how disruptions in normal journalistic processes hamper accurate reporting and fact-checking.

Sandra Lamb is an award-winning author of many books, including; Writing Well for Business Success; 3000 Power Words and Phrases for Effective Performance; How to Write It: A Complete Guide to Everything You’ll Ever Write; and Personal Notes How to Write from the Heart for Any Occasion. She is a former columnist for The Denver Post and former Rocky Mountain News, and she has written relationship/psychology articles for national women’s magazines such as Family Circle and Woman’s Day; and health care and science articles for such publications as Scientific American, AARP, and many others.

Daily Remedy

Daily Remedy

Dr. Jay K Joshi serves as the editor-in-chief of Daily Remedy. He is a serial entrepreneur and sought after thought-leader for matters related to healthcare innovation and medical jurisprudence. He has published articles on a variety of healthcare topics in both peer-reviewed journals and trade publications. His legal writings include amicus curiae briefs prepared for prominent federal healthcare cases.

Leave a Reply

Your email address will not be published. Required fields are marked *

Videos

2027 Medicare Advantage & Part D Advance Notice

BIIB080 in Mild Alzheimer’s Disease: What a Phase 1b Exploratory Clinical Analysis Can—and Cannot—Tell Us

BIIB080 in Mild Alzheimer’s Disease: What a Phase 1b Exploratory Clinical Analysis Can—and Cannot—Tell Us

Can lowering tau biology translate into a clinically meaningful slowing of decline in people with early symptomatic Alzheimer’s disease? That is the practical question behind BIIB080, an intrathecal antisense therapy designed to reduce production of tau protein by targeting the tau gene transcript. In a phase 1b program originally designed for safety and dosing, investigators later examined cognitive, functional, and global outcomes as exploratory endpoints. The clinical question matters because current disease-modifying options primarily target amyloid, while tau pathology tracks...

Read more

Join Our Newsletter!